Modality
ASO
MOA
PLK4i
Target
CD3
Pathway
Autophagy
Atopic DermCholangiocarcinomaPBC
Development Pipeline
Preclinical
~Apr 2015
→ ~Jul 2016
Phase 1
~Oct 2016
→ ~Jan 2018
Phase 2
Apr 2018
→ Dec 2031
Phase 2Current
NCT08028740
1,121 pts·Cholangiocarcinoma
2022-04→2030-11·Completed
NCT08515922
1,323 pts·Atopic Derm
2018-04→2031-12·Terminated
2,444 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-11-054.6y awayPh2 Data· Cholangiocarcinoma
2031-12-205.7y awayPh2 Data· Atopic Derm
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Termina…
P2
Complet…
Catalysts
Ph2 Data
2030-11-05 · 4.6y away
Cholangiocarcinoma
Ph2 Data
2031-12-20 · 5.7y away
Atopic Derm
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08028740 | Phase 2 | Cholangiocarcinoma | Completed | 1121 | SRI-4 |
| NCT08515922 | Phase 2 | Atopic Derm | Terminated | 1323 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| MDG-4513 | Madrigal Pharma | Phase 1/2 | CD3 | |
| Liravorutinib | Biomea Fusion | Phase 1/2 | GPRC5D | |
| SGM-7896 | Sangamo | Preclinical | CD3 | |
| CSL-8153 | CSL Limited | Approved | CD3 |